TGIA
IBRX icon

Torrey Growth & Income Advisors’s ImmunityBio IBRX Stock Holding History

Torrey Growth & Income Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
118,860
+63,410
+114% +$480K 0.35% 45
2026
Q1 		$405K Buy
+55,450
New +$380K 0.17% 71

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Torrey Growth & Income Advisors's IBRX Position: Q2 2026 in Review

Torrey Growth & Income Advisors increased its ImmunityBio (IBRX) stake by 114% in Q2 2026, buying an estimated $480K and bringing the position to 118,860 shares worth $1.03M. The position accounts for 0.35% of the portfolio, ranked #45.

Torrey Growth & Income Advisors first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Torrey Growth & Income Advisors held 118,860 shares of ImmunityBio worth $1.03M as of Q2 2026.
  • Torrey Growth & Income Advisors bought 63,410 ImmunityBio shares in Q2 2026, an estimated $480K.
  • ImmunityBio made up 0.35% of Torrey Growth & Income Advisors's portfolio in Q2 2026, its #45 holding.
  • Torrey Growth & Income Advisors first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Torrey Growth & Income Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.